Andorra Health Watch
SEE OTHER BRANDS

Exploring the health and wellness news of Andorra

Andorra Health Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Andorra Health Watch.

Press releases published on September 4, 2025

Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases

Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases

O3R-5671 is designed to overcome the limitations of first-generation SIK inhibitors, providing a potential new oral treatment option for multiple autoimmune diseases Clinical Trial Application approval marks Onco3R’s transition into a clinical-stage …

PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025

PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025

PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology announces that its CSO, Thierry Bordet Ph.D., will present …

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

MINNEAPOLIS and BRISBANE, Australia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting- …

Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed

Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed

Company expects to fully repay existing financial debts in 2026 NCX 470 NDA submissions in U.S. (H1 2026) and subsequently in China Milestones payable on U.S. NDA submission and on approval Glaukos extends NCX 1728 research agreement Future strategic …

Nicox prévoit de rembourser intégralement ses dettes financières, NCX 470 ayant été dé-risqué et licencié dans le monde entier

Nicox prévoit de rembourser intégralement ses dettes financières, NCX 470 ayant été dé-risqué et licencié dans le monde entier

4 septembre 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui qu’elle prévoit de rembourser l’ …

Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically …

Communiqué de presse : L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique

Communiqué de presse : L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique

L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique L’amlitelimab, administré toutes les quatre semaines ou …

Kuros Biosciences announces changes in the Board of Directors

Kuros Biosciences announces changes in the Board of Directors

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences announces changes in the Board of Directors Schlieren (Zurich), Switzerland, September 4, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation …

ProductLife Group Expands to Deliver Localized Expertise  & Enhanced Client Support in Japan

ProductLife Group Expands to Deliver Localized Expertise & Enhanced Client Support in Japan

PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- ProductLife Group (PLG) is proud to announce the opening of its newest office in Japan, reinforcing its commitment to meeting evolving client needs and market demands. This expansion enhances capacity, strengthens …

JUST ON SLEEP Officially Launches on Shopee Singapore, Redefining Sleep Safety and Wellness

JUST ON SLEEP Officially Launches on Shopee Singapore, Redefining Sleep Safety and Wellness

SINGAPORE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- JUST ON SLEEP, a smart contactless sleep monitoring device developed by Sewon Intelligence, has recently launched in Singapore via Shopee, making advanced sleep wellness and safety solutions more accessible to …

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions